Feb 28,2023

Qure.ai and Therapixel announce partnership to improve access to breast cancer detection through AI

Qure.ai, a leading medical Artificial Intelligence (AI) imaging company, announced a new partnership with Therapixel, a French firm that uses AI to improve the early breast cancer detection. Qure.ai will be a global distributor for Therapixel’s MammoScreen®. MammoScreen enables radiologists to read large numbers of screening mammograms in 2D and 3D more confidently, improving breast cancer detection accuracy and efficiency. Qure.ai now offers one of the most comprehensive imaging AI portfolios globally, covering lung and breast cancer, among other disease areas.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 28,2023 TOP STORY

PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live

PAVmed Inc, a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc., today announced that the Veris Cancer Care Platform™ (Veris CCP), designed to enhance personalized cancer care through remote patient monitoring (RPM), is now live following successful onboarding of the first cohort of cancer patients and their clinicians. Enrolled patients received a VerisBox™ and were then successfully trained to use its Veris-branded Bluetooth-enabled connected health care devices to transmit real-time physiologic data to the cloud-based Veris CCP clinician portal via an embedded cellular connection. The app is now available on the Apple App Store and Google Play.

PRODUCT

#rpm

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 28,2023

Digital Pathology Market Size Worth USD 2,271.3 Million in 2030 | Emergen Research

The global digital pathology market is expected to experience significant growth in the coming years. According to a report by Grand View Research, Inc., the market size is projected to reach USD 2,271.3 Million in 2030, growing at a CAGR of 13.46% during the forecast period. The increasing prevalence of chronic diseases, rising demand for personalized medicine, and the growing adoption of digital pathology for cancer diagnosis and treatment planning are some of the key drivers of this growth.

#software

View Analyst & Ambassador Comments
Go to original news
Feb 28,2023

BioAI Health Announces the Appointment of Martin Baatz, PhD, as Chief Operating Officer

BioAI Health, an emerging leader in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, today announced the appointment of Martin Baatz, PhD, as Chief Operating Officer of the company. In this role, Baatz will be deeply involved in scaling the company's growth and global business operations.

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program

Radiology Imaging Associates, a division of RadNet, Inc. (NASDAQ: RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service, which works in concert with a patient's annual breast screening regimen. For an additional fee, patients can receive an advanced screening mammography service including (i) the application of Saige-Dx, an FDA-cleared artificial intelligence (AI) technology powered by DeepHealth; (ii) an additional AI-driven review applied to certain suspicious exams and findings; (iii) an in-depth personalized lifetime risk assessment for breast cancer; and (iv) a dedicated 1-800 support line for questions about certain aspects of the patient's reports. EBCD presents a significantly improved level of accuracy in breast cancer detection, empowering women to take greater control of their health.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 07,2023 TOP STORY

PreciseDx Receives New York State Approval for an AI-Enabled Breast Diagnostic

PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced that the New York State Department of Health (NYSDOH) has approved the PDxBr, a Lab Developed Test (LDT) designed to enrich breast cancer grading and improve risk categorization. With this approval, PreciseDx can now begin commercially testing patient samples in the state of New York through its CLIA certified laboratory.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 15,2023

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three phase 3 trials, represent the first validation of any gene-expression biomarker on pre-treatment biopsy samples from prospective randomized trials, and suggest the Decipher test provides clinically useful prognostic information to help personalize shared treatment decision-making.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 15,2023

Cancer Symptom Algorithm Presented in JNCCN Can Aid Doctors in Predicting Patients at Risk for Unplanned Emergency Visits

New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs. The researchers used the Edmonton Symptom Assessment System-Revised (ESASr) as a measurement tool for the most-common symptoms experienced by people with cancer. After classifying each patient's symptom complexity based on the number and severity of symptoms reported, the researchers correlated the symptom complexity with the odds of having an ED visit within a week.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

Theragent Embraces Pharma 4.0 with AI Software Provider, Insight68

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider that aims to digitalize and streamline the cell therapy manufacturing process. This partnership reinforces Theragent's commitment to 100% digital batch record compliance and elevates the company's reputation as a leading CDMO in the current biopharma manufacturing transformation.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023 TOP STORY

Qure.ai Awarded EU MDR Certification for Its AI solutions

Qure.ai, a leading provider of artificial intelligence (AI) software for medical imaging, today announced that its solutions were awarded the CE Class IIb certification for medical devices under the European Union Medical Device Regulation (Regulation (EU) 2017/745) (EU-MDR). Qure.ai now offers one of the most comprehensive, certified portfolios of AI-based detection devices for radiology in the EU, spanning over 31 countries. Qure’s AI helps detect abnormalities from multiple radiology modalities including Chest X-rays, Chest CT, Head CT, and Musculoskeletal X-rays. These medical devices are cutting-edge AI software that assist radiologists in interpreting radiological scans in different healthcare settings.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY